7-Fluoroindazoles as potent and selective inhibitors of factor Xa

Journal of Medicinal Chemistry

Volumn 51, Issue 2, 2008, Pages 282-297

  Lee, Yu Kai ^a   Parks, Daniel J ^a   Lu, Tianbao ^a   Thieu, Tho V ^a,b   Markotan, Thomas ^a   Pan, Wenxi ^a   McComsey, David F ^a   Milkiewicz, Karen L ^a,b   Crysler, Carl S ^a   Ninan, Nisha ^a   Abad, Marta C ^a   Giardino, Edward C ^a   Maryanoff, Bruce E ^a   Damiano, Bruce P ^a   Player, Mark R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [1 (3 AMINOMETHYLPHENYL) 3 METHYL 1H INDAZOL 6 YL]PHENYL]PIPERIDIN 2 ONE; 1 [4 [1 (3 AMINOMETHYLPHENYL) 3 METHYL 1H INDAZOL 6 YL]PHENYL]PYRROLIDIN 2 ONE; 1 [4 [1 (3 AMINOMETHYLPHENYL) 7 FLUORO 3 METHYL 1H INDAZOL 6 YL]PHENYL]PIPERIDIN 2 ONE; 1 [4 [1 (3 AMINOMETHYLPHENYL) 7 FLUORO 3 METHYL 1H INDAZOL 6 YL]PHENYL]PYRROLIDIN 2 ONE; 7 FLUOROINDAZOLE DERIVATIVE; 7 FLUOROINDAZOLYL DERIVATIVE; AMIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBONYL DERIVATIVE; FLUORINE DERIVATIVE; GLYCINE; HYDROGEN; INDAZOLE DERIVATIVE; NITROGEN; PEPTIDE DERIVATIVE; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BETA SHEET; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYDROGEN BOND; PROTEIN DOMAIN; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CRYSTALLOGRAPHY, X-RAY; FACTOR XA; HUMANS; HYDROGEN BONDING; INDAZOLES; MICROSOMES, LIVER; MODELS, MOLECULAR; PROTEIN CONFORMATION; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 38349194790     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701217r     Document Type: Article

References (47)

1. Rosamond, W.; Flegal, K.; Friday, G.; Furie, K.; Go, A.; Greenlund, K.; Hasse, N.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lloyd-Jones, D.; McDermott, M.; Meigs, J.; Moy, C.; Nichol, G.; O'Donnell, C. J.; Roger, V.; Rumsfeld, J.; Sortie, P.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Hong, Y. Heart Disease and Stroke Statistics - 2007 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115, e69-e171.
2. DeFrances, C. J.; Hall, M. J. 2005 National Hospital Discharge Survey. Advance Data from Vital and Health Statistics No. 385; DHHS Publication (PHS) 2007-1250; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics: Hyattsville, MD, 2007.
3. Statistical Fact Sheet. Miscellaneous 2007 Update; American Heart Association: Dallas, TX, 2007.
4. Nutescu, E. A.; Shapiro, N. L.; Chevalier, A.; Amin, A. N. A Pharmacologic Overview of Current and Emerging Anticoagulants. Cleveland Clin. J. Med. 2004, 72 (Suppl. 1), S2-S6.
5. Hirsh, J.; Dalen, J. E.; Anderson, D. R.; Poller, L.; Bussey, H.; Ansell, J.; Deykin, D. Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest 2001, 119, S8-S21.
6. Hirsh, J.; Warkentin, T. E.; Shaughnessy, S. G.; Anand, S. S.; Halperin, J. L.; Raschke, R.; Granger, C.; Ohman, E. M.; Dalen, J. E. Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest 2001, 119, S64-S94.
7. Perzborn, E.; Strassburger, J.; Wilmen, A.; Pohlmann, J.; Roehrig, S.; Schlemmer, K.-H.; Straub, A. In Vitro and in Vivo Studies of the Novel Antithrombotic Agent BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor. J. Thromb. Haemostasis 2005, 3, 514-521.
8. Kubitza, D.; Becka, M.; Voith, B.; Zuehlsdorf, M.; Wensing, G. Safety, Pharmacodynamics, and Pharmacokinetics of Single Doses of BAY 59-7939, an Oral, Direct Factor Xa Inhibitor. Clin. Pharmacol. Ther. 2005, 78, 412-421.
9. Wong, P. C.; Pinto, D. J. P.; Knabb, R. M. Nonpeptide Factor Xa Inhibitors: DPC423, a Highly Potent and Orally Bioavailable Pyrazole Antithrombotic Agent. Cardiovasc. Drug Rev. 2002, 20, 137-152.
10. Wong, P. C.; Crain, E. J.; Watson, C. A.; Zaspel, A. M.; Wright, M. R.; Lam, P. Y.; Pinto, D. J. P.; Wexler, R. R.; Knabb, R. M. Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits. J. Pharmacol. Exp. Ther. 2002, 993-1000.
11. Sanderson, P. E. J. Anticoagulants: Inhibitors of Thrombin and Factor Xa. In Annual Reports in Medicinal Chemistry; Doherty, A., Ed.; Academic Press: San Diego, CA, 2001; Vol. 36, pp 79-98.
12. Quan, M.; Smallheer, J. The Race to an Orally Active Factor Xa Inhibitor: Recent Advances. Curr. Opin. Drug Discovery Dev. 2004, 7, 460-469.
13. Alexander, J. H.; Singh, K. P. Inhibition of Factor Xa: A Potential Target for the Development of New Anticoagulants. Am. J. Cardiovasc. Drugs 2005, 5, 279-290.
14. Haas, S. New Anticoagulant Drugs: A Critical Perspective. Curr. Hematol. Rep. 2005, 4, 335-338.
15. Hirsh, J.; O'Donnell, M.; Weitz, J. I. New Anticoagulants. Blood 2005, 105, 453-463.
16. McBride, B. F. A Preliminary Assessment of the Critical Differences between Novel Oral Anticoagulants Currently in Development. J. Clin. Pharmacol. 2005, 45, 1004-1017.
17. Ng, H. J.; Crowther, M. A. New Anti-Thrombotic Agents: Emphasis on Hemorrhagic Complications and Their Management. Semin. Hematol. 2006, 43, S77-S83.
18. Pinto, D. J. P.; Orwat, M. J.; Wang, S.; Fevig, J. M.; Quan, M. L.; Amparo, E.; Cacciola, J.; Rossi, K. A.; Alexander, R. S.; Smallwood, A. M.; Luettgen, J. M.; Liang, L.; Aungst, B. J.; Wright, M. R.; Knabb, R. M.; Wong, P. C.; Wexler, R. R.; Lam, P. Y. S. Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl] -3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa. J. Med. Chem. 2001, 44, 566-578.
19. Quan, M. L.; Lam, P. Y. S.; Han, Q.; Pinto, D. J. P.; He, M. Y.; Li, R.; Ellis, C. D.; Clark, C. G.; Teleha, C. A.; Sun, J.-H.; Alexander, R. S.; Bai, S.; Luettgen, J. M.; Knabb, R. M.; Wong, P. C.; Wexler, R. R. Discovery of 1-(3′-Aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro- 4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H- pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor. J. Med. Chem. 2005, 48, 1729-1744.
20. Lassen, M. R.; Davidson, B. L.; Callus, A.; Pineo, G.; Ansell, J.; Deitchman, D. A Phase II Randomized, Double-Blind, Five-Arm, Parallel-Group, Dose-Response Study of a New Oral Directly-Acting Factor Xa Inhibitor, Razaxaban, For the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery: On Behalf of the Razaxaban Investigators. Blood 2003, 102, 15a, Abstract 41.
21. Fevig, J. M.; Cacciola, J.; Buriak, J., Jr; Rossi, K. A.; Knabb, R. M.; Luettgen, J. M.; Wong, P. C.; Bai, S. A.; Wexler, R. R.; Lam, P. Y. S. Preparation of 1-(4-Methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin- 7(6H)-ones as Potent, Selective and Bioavailable Inhibitors of Coagulation Factor Xa. Bioorg. Med. Chem. Lett. 2006, 16, 3755-3760.
22. Pinto, D. J. P.; Orwat, M. J.; Quan, M. L.; Han, Q.; Galemmo, R. A., Jr.; Amparo, E.; Wells, B.; Ellis, C.; He, M. Y.; Alexander, R. S.; Rossi, K. A.; Smallwood, A.; Wong, P. C.; Luettgen, J. M.; Rendina, A. R.; Knabb, R. M.; Mersinger, L.; Kettner, C.; Bai, S.; He, K.; Wexler, R. R.; Lam, P. Y. S. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R) -hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5, 6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a Highly Potent, Selective, Efficacious, And Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa. Bioorg. Med. Chem. Lett. 2006, 16, 4141-4147.
23. Li, Y.-L.; Fevig, J. M.; Cacciola, J.; Buriak, J.; Rossi, K. A.; Jona, J.; Knabb, R. M.; Luettgen, J. M.; Wong, P. C.; Bai, S. A.; Wexler, R. R.; Lam, P. Y. S. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as Potent, Selective, And Efficacious Inhibitors of Coagulation Factor Xa. Bioorg. Med. Chem. Lett. 2006, 16, 5176-5182.
24. Pinto, D. J. P.; Galemmo, R. A.; Quan, M. L.; Orwat, M. J.; Clark, C.; Li, R.; Wells, B.; Woerner, F.; Alexander, R. S.; Rossi, K. A.; Smallwood, A.; Wong, P. C.; Luettgen, J. M.; Rendina, A. R.; Knabb, R. M.; He, K.; Wexler, R. R.; Lam, P. Y. S. Discovery of Potent, Efficacious, ad Orally Bioavailable Inhibitors of Blood Coagulation Factor Xa with Neutral P1 Moieties. Bioorg. Med. Chem. Lett. 2006, 16, 5584-5589.
25. Qiao, J. X.; King, S. R.; Wong, P. C.; He, K.; Rendina, A. R.; Luettgen, J. M.; Knabb, R. M.; Wexler, R. R.; Lam., P. Y. S. Highly Potent and Selective Factor Xa Inhibitors Containing Alpha-Substituted Arylcycloalkyl P4 Residues: SAR Studies of C3 Substitution and the Aryl Binding Site. Presented at the 233rd National Meeting of the American Chemical Society, Chicago, IL, March 25-29, 2007; MEDI 388.
26. Qiao, J. X.; Cheng, X.; Smallheer, J. M.; Galemmo, R. A.; Drummond, S.; Pinto, D. J. P.; Cheney, D. L.; He, K.; Wong, P. C.; Luettgen, J. M.; Knabb, R. M.; Wexler, R. R.; Lam, P. Y. S. Pyrazole-Based Factor Xa inhibitors Containing N-Arylpiperidinyl P4 Residues. Bioorg. Med. Chem. Lett. 2007, 17, 1432-1437.
27. Kreutter, K. D.; Lee, L.; Lu, T.; Mohan, V.; Patel, S.; Huang, H.; Xu, G.; Fitzgerald, M. P. Preparation of (Pyridinylalkylamino)benzeneacetamides and Related Compounds as Protease Inhibitors for Use as Anticoagulants; WO 2004091613 A2 20041028, 2004.
28. Kreutter, K. D.; Lee, L.; Lu, T.; Mohan, V.; Patel, S.; Huang, H.; Xu, G.; Fitzgerald, M.; Crysler, C.; Player, M. R.; Giardino, E. C.; Maryanoff, B. E.; Damiano, B. P.; Tomczuk, B. E.; Huebert, N. D.; Eisennagel, S.; Dasgupta, M.; Spurltno, J. C.; McMillan, M. Novel Orally Bioavailable Thrombin Inhibitors: Cyanofluorophenylacetic Acid Derivatives. Presented at the 229th National Meeting of the American Chemical Society, San Diego, CA, March 13-17, 2005; MEDI-243.
29. Lee, L.; Kreutter, K. D.; Pan, W.; Crysler, C.; Spurlino, J.; Player, M. R.; Tomczuk, B.; Lu, T. 2-(2-Chloro-6-fluorophenyl)acetamides as Potent Thrombin Inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6266-6269.
30. Lee, L.; Kreutter, K. D.; Pan, W.; Lu, T.; Crysler, C.; Eisennagel, S.; MacMillan, M.; Spurlino, J.; Tomczuk, B.; Player, M.; Mohan, V. Potent Small Molecule, Non-Peptidic Chlorophenyl Acetamide Thrombin Inhibitors. Presented at the 229th National Meeting of the American Chemical Society, San Diego, CA, March 13-17, 2005; 2005; MEDI244.
31. Parlow, J. J.; Stevens, A. M.; Stegeman, R. A.; Stallings, W. C.; Kurumbail, R. G.; South, M. S. Synthesis and Crystal Structures of Substituted Benzenes and Benzoquinones as Tissue Factor VIIa Inhibitors. J. Med. Chem. 2003, 46, 4297-4312.
32. Mongin, F.; Schlosser, M. Regioselective Ortho-Lithiation of Chloro and Bromo Substituted Fluoroarenes. Tetrahedron Lett. 1996, 37, 6551-6554.
33. Lam, P. Y. S.; Clark, C. G.; Li, R.; Pinto, D. J. P.; Orwat, M. J.; Galemmo, R. A.; Fevig, J. M.; Teleha, C. A.; Alexander, R. S.; Smallwood, A. M.; Rossi, K. A.; Wright, M. R.; Bai, S. A.; He, K.; Luettgen, J. M.; Wong, P. C.; Knabb, R. M.; Wexler, R. R. Structure-Based Design of Novel Guanidine/ Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants. J. Med. Chem. 2003, 46, 4405-4418.
34. Recently two similar syntheses of indazoles were reported: (a) Lukin, K.; Hsu, M. C.; Fernando, D.; Leanna, M. R. New Practical Synthesis of Indazoles via Condensation of o-Fluorobenzaldehydes and Their O-Methyloximes with Hydrazine. J. Org. Chem. 2006, 71, 8166-8172.
35. (b) Viña, D.; del Olmo, E.; López-Pérez, J. L.; Feliciano, A. S. Regioselective Synthesis of 1-Alkyl- or 1-Aryl-1H-Indazoles via Copper-Catalyzed Cyclizations of 2-Haloarylcarbonylic Compounds. Org. Lett. 2007, 9, 525-528.
36. Ishiyama, T.; Murata, M.; Miyaura, N. Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters. J. Org. Chem. 1995, 60, 7508-7510.
37. Bjoerk, P.; Aakermann, T.; Hoernfeldt, A.-B.; Gronowitz, S. Improved Syntheses of Thieno[2,3-b]- and [3,2-b]-Fused Naphthyridines. J. Heterocycl. Chem. 1995, 32, 751-754.
38. Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in Medicinal Chemistry. ChemBioChem 2004, 5, 637-643.
39. Razgulin, A. V.; Mecozzi, S. Binding Properties of Aromatic Carbon-Bound Fluorine. J. Med. Chem. 2006, 49, 7902-7906.
40. Dunitz, J. D.; Taylor, R. Organic Fluorine Hardly Ever Accepts Hydrogen Bonds. Chem. - Eur. J. 1997, 3, 89-98.
41. Carosati, E.; Sciabola, S.; Cruciani, G. Hydrogen Bonding Interactions of Covalently Bonded Fluorine Atoms: From Crystallographic Data to a New Angular Function in the GRID Force Field. J. Med. Chem. 2004, 47, 5114-5125.
42. Howard, J. A. K.; Hoy, V. J.; O'Hagan, D.; Smith, G. T. How Good Is Fluorine as a Hydrogen Bond Acceptor? Tetrahedron 1996, 52, 12613-12622.
43. Dong, C.; Huang, F.; Deng, H.; Schaffrath, C.; Spencer, J. B.; O'Hagan, D.; Naismith, J. H. Crystal Structure and Mechanism of a Bacterial Fluorinating Enzyme. Nature 2004, 427, 561-565.
44. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
45. Brunger, A. T. X-PLOR: A System for X-ray Crystallography and NMR, version 3.1; Yale University Press: New Haven, CT, 1993; p 405.
46. Maignan, S.; Guilloteau, J. P.; Pouzieux, S.; Choi-Sledeski, Y. M.; Becker, M. R.; Klein, S. I.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V. Crystal Structures of Human Factor Xa Complexed with Potent Inhibitors. J. Med. Chem. 2000, 43, 3226-3232.
47. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in These Models. Acta Crystallogr. 1991, A47, 110-119.